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Recent analyses of next-generation sequencing datasets have shown that cell-specific regulatory elements in stem
cells are marked with distinguishable patterns of transcription factor (TF) binding and epigenetic marks. For example,
we recently demonstrated that promoters of cell-specific genes are covered with expanded trimethylation of histone
H3 at lysine 4 (H3K4me3) marks (i.e., broad H3K4me3 domains). Moreover, binding of specific TFs, such as OCT4,
NANOG, and SOX2, have been shown to play a critical role in maintaining the pluripotency of stem cells. Despite
these observations, a systematic exploration of genomic and epigenomic features of stem-cell-specific gene promoters
has not been conducted. Advanced machine-learning models can capture distinguishable genomic and epigenomic
characteristics of stem-cell-specific promoters by taking advantage of the wealth of publicly available datasets. Here, we
propose a three-step framework to discover novel data characteristics of high-throughput next generation sequencing
datasets that distinguish pluripotency genes in human and mouse embryonic stem cells (ESCs). Our framework
involves: i) feature extraction to identify novel features of genomic datasets; ii) feature selection using a logistic
regression model combined with the Least Absolute Shrinkage and Selection Operator (LASSO) method to find
the most critical datasets and features; and iii) cross validation with features selected using LASSO method to
assess the predictive power of selected data features in distinguishing pluripotency genes. We show that specific
epigenetic marks, and specific features of these marks, are enriched at pluripotency gene promoters. Moreover,
we also assess both the individual and combined effect of TF binding, epigenetic mark deposition, gene expression
datasets for marking pluripotency genes. Our findings are consistent with the existence of a conserved, complex and
integrative genomic signature in ESCs that can be exploited to flag important candidate pluripotency genes. They also
validate our computational framework for fostering a deeper understanding of genomic datasets in stem cells, in the
future, could be extended to study cell-type-specific genomic landscapes in other cell types.
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In this study, we built a machine-learning framework to
identify genomic and epigenomic characteristics of pluri-
potency gene promoters in embryonic stem cells (ESCs)
from human and mouse. Our framework de novo identified
several predictors previously linked to pluripotency genes:
i) an enrichment for known pluripotency regulators (e.g.
OCT4 binding), ii) a signature of increased H3K4me3
spread along genomic loci and iii) increased marks of regu-
lation of transcriptional elongation and initiation. These
findings are consistent with the existence of a complex and
integrative epigenomic signature that, using our model,
could be exploited to flag novel important pluripotency
genes. Furthermore, the conservation of several features of
the pluripotency signature in mouse and human ESCs sug-
gests the existence of common specific constraints for the
chromatin environment of genes involved in stem cell
pluripotency. We also found that certain characteristics of
these datasets are highly correlated, some of which proved
very predictive for discriminating stem cell promoters from
non-specific promoters, such as the spread (breadth) of
H3K4me3 domains found around the gene promoter. Fi-
nally, our results revealed the importance of considering
additional features of epigenomic signal, like the spread of
a histone modification mark over a genomic locus (i.e.,
peak breadth), or the number of times a gene is marked by
a histone mark or bound by a protein. Our computational
evaluation of these combinatorial data features showed
that, although these features are significantly predictive in
marking known pluripotency genes, their predictive power
remains modest (AUC~0.7). This implies that pluripotency
functions are likely regulated by factors other than the
genomic and epigenomic features at gene promoters
that we integrated in our models, for instance exist-
ence of distal regulatory elements or three-dimensional
chromatin interactions between promoter and enhancers.
In the future, the predictive power of such models might
be expanded with the inclusion of novel types of dataset
and further feature engineering. We believe our findings
will enable the community to integrate novel and
important data characteristics into their studies and,
in turn, foster a deeper understanding of specific




Stem cells have the capability to self-renew, and daughter
cells can then differentiate into various tissue lineages.
Embryonic stem cells (ESCs) are pluripotent and can give
rise to virtually any cell type within the adult organism. In
addition to their use as research tools for understanding
self-renewal, cellular differentiation and development,
ESCs have enormous potential for a range of regenerativecell-based therapies. The pluripotency state of ESCs can
be largely mimicked by induced Pluripotent Stem Cells
(iPSCs), which are reprogrammed from differentiated
cells, and could be a great source of immunogen-free cells
for cell based-therapeutics in humans. Elucidating the fun-
damental mechanisms of pluripotency is critical to assess
that differentiated ESC- or iPSC-derived cells are fully
committed to their lineage, or that iPSCs have, and main-
tain, important characteristics of stem cells. Thus, further
characterization of the genomic and epigenomic state of
genes that play a role in stem cell pluripotency is critical
to both understanding the molecular basis of lineage com-
mitment and putting stem cells into safe medical use.
With the decreasing cost of sequencing, large volumes
of data are generated via Chromatin Immunoprecipita-
tion followed by high-throughput sequencing (ChIP-seq)
technology to profile TF binding and histone modifica-
tion landscapes in human and mouse embryonic stem
cells (ESCs). Studies of genome-wide sequencing data-
sets have revealed genomic features specific to genes
critical for pluripotency. For example, promoters of plur-
ipotency genes are more likely to be marked by broader
H3K4me3 domains (i.e., expanded DNA regions marked
with H3K4me3) in human and mouse ESCs [2]. Simi-
larly, specific TFs, such as OCT4, NANOG and SOX2,
are observed to play critical roles in maintaining the
pluripotency functions of stem cells by binding to the
promoters of critical genes to regulate their expression
[3]. However, most evidence for genomic and epige-
nomic signatures associated with pluripotency genes to
date comes from anecdotal observations [4]. Integrative
computational models will enable us to springboard to
systematic discoveries by taking advantage of vast
amounts of genomic and epigenomic information gener-
ated in stem cells and collected in public data repositories.
In this study, we built a statistical framework based on
least absolute shrinkage and selection operator (LASSO)
and logistic regression [5] to: i) extract novel features from
genomic and epigenomic datasets, such as the length of
genomic regions with modified histones, which recently
was shown to be associated with cell identity [2, 6–8], ii)
identify the genomic and epigenomic signatures specific
to the promoters of pluripotency genes to discover the
genomic signature for pluripotency, and iii) assess the
power of this genomic signature in marking known pluri-
potency genes and discovering novel ones. Through min-
ing of next generation sequencing data in mouse and
human ESCs, our computational platform allowed us to
quantify the relationship of diverse epigenomic datasets to
stem-cell-specific gene promoters, as well as to systemat-
ically assess the predictive power of these signatures.
LASSO is a regression method that enables effective
feature selection and model interpretation. LASSO-type
regularizations have been applied to a wide range of
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years, it has been successfully applied on learning diverse
genomic and epigenomic patterns, including predicting
targets of microRNAs from gene expression data [11],
gene expression levels from histone modification marks
[10], and from copy number variations [9]. In this manu-
script, we employed LASSO models to address the fol-
lowing questions in human and mouse ESCs: is there a
specific (epi-)genomic signature that marks pluripotency
gene promoters in human and mouse stem cells? Can
this signature be used to predict novel pluripotency
genes? Are features of this pluripotency signature con-
served between human and mouse embryonic stem
cells? Indeed, we found a genomic signature, predictive
of pluripotency in human and mouse embryonic stem
cells, which is partially conserved across both organisms.
Our main contribution is, in addition to utilizing
LASSO-type regularization to effectively address the
above-mentioned questions; with our computational
models we quantified the predictive power of this signa-
ture for identifying important genes for ‘stem cell state’.
Materials and methods
Epigenomic data collection and processing
We collected and analyzed publicly available ChIP-seq
datasets assaying histone modification and protein-
binding profiles in the human (h) ESC line H1 and in
mouse (m) ESCs using public databases. Briefly, we
processed the raw ChIP-seq files and filtered out low
quality reads with less than 80 % of read length at Phred
score >15. Reads were mapped to their respective refer-
ence genomes (hg19 for human and mm9 for mouse)
using the Bowtie 1 algorithm (version 0.12.7) [13]. ChIP-
seq peaks were called with MACS algorithm (version
2.08) [14] (using the “—broad” option for histone marks),
and using the corresponding control input data. We
assigned peaks to the gene with the closest transcription
start site (TSS) using the HOMER toolkit [15]. In hESCs,
we processed 25 histone modification marks, including
acetylations and methylations, in addition to 43 protein-
binding profiles. In mESCs, we analyzed eight epigenetic
marks and 59 protein-binding profiles. Additional file 1:
Table S1 lists the epigenetic marks and protein-binding
datasets in hESCs and mESCs that were analyzed and
used in our computational framework, as well as the ac-
cession numbers for the raw data used in this analysis.
Identification of ‘canonical’ pluripotency genes
In order to learn the pluripotency signature, we compiled
a set of “gold-standard” pluripotency genes to compare
against genes with no known pluripotency functions. For
this purpose, we used data from the ESCAPE database
[16], which houses genes with potential pluripotency func-
tions derived from multiple RNAi screening studies. Inaddition to the ESCAPE dataset, we also incorporated the
curated list of known pluripotency genes [17]. In total, we
used 397 and 728 putative or known pluripotency genes
in hESC and mESC models, respectively. As negative con-
trols, we randomly selected genes that have no known role
in pluripotency. This process, in which we used the
known pluripotency genes and selected negative controls
randomly, was repeated 500 times and, at each run, non-
pluripotency genes were selected in equal numbers rela-
tive to their pluripotency gene counterparts.
Computational framework
We designed a computational platform enabling system-
atic identification of precise genomic and epigenomic
signatures at known pluripotency genes, as well as a
means of assessing their power in predicting novel genes
that play a critical role in pluripotency. This platform
also integrates diverse and complementary datasets in
human and mouse stem cells residing in different public
databases. Our computational framework is composed
of three main steps (Fig. 1):
1) Extracting relevant data features from histone
modification and transcription binding ChIP-seq
datasets;
2) Selecting the most predictive datasets and their data
features (i.e., pluripotency signature) via a multi-step
machine-learning model that integrates a logistic re-
gression model with the Least Absolute Shrinkage
and Selection Operator (LASSO) method;
3) Assessing the predictive power of the inferred
pluripotency signature using cross validation.
This framework enables us to: i) discover genomic sig-
natures specific to pluripotency genes, (i.e., pluripotency
signature); ii) infer the contribution of each dataset and
data feature(s) to the pluripotency signature; iii) identify
similarities and differences between human and mouse
pluripotency signatures; and iv) discover novel pluripo-
tency genes through computational prediction.
Step 1. Feature extraction The first step of our frame-
work involves extracting relevant data features from
ChIP-seq datasets for human and mouse genes. Using
the annotations of peaks to genes for every gene and for
each ChIP-seq dataset, we extracted the following fea-
tures from the data: peak count, distance to closest an-
notated Transcriptional Start Site (TSS), peak breadth.
These features should be able to capture different as-
pects of the signal with potential biological relevance.
First, the number of peaks (i.e., count) in a dataset anno-
tating to a specific gene (e.g., number of OCT4 peaks as-
sociated with a gene; defaults to 0 if there are no peaks)
will capture the potential existence of multiple discrete
Fig. 1 Scheme for our computational framework. A three-step framework to detect genomic and epigenomic characteristics of pluripotency gene
promoters in human and mouse embryonic stem cells
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could have implications on the associated transcriptional
response [18]. Secondly, we included the signed distance
between the TSS of the annotated gene and the genomic
location of the closest peak annotating to it (e.g., distance
of the closest OCT4 peak to the gene; in the case of mul-
tiple peaks, the closest peak is taken into account) as dis-
tance implied to be relevant for genomic signals [3],
where negative values mean upstream of the TSS and
positive values mean downstream of the TSS. Another im-
portant feature is the breadth, which is the genomic
spread of the broadest peak marking the gene (e.g., the
breadth of H3K4me3 peak marking a gene), a chromatin
feature that has been increasingly linked to important bio-
logical functions [2, 6–8, 19]. For each ChIP-seq dataset,
we extracted the aforementioned features for all genes in
hESCs and mESCs, resulting respectively in 76×3 and
63×3 data features for characterizing the genomic and epi-
genomic landscape. In addition, we also took advantage of
gene expression information using RNA-seq datasets from
human (GSE30567) and mouse (ERP002100) ESCs in our
models. Following the common practice in building
LASSO-type models, we used a Z-score normalization ap-
proach on all input features including histone modifica-
tion, protein binding, and gene expression features in
order to take care of scaling differences in the data.Step 2. Feature selection The second step aims to iden-
tify data features from epigenetic, TF binding, and gene
expression datasets that are specific to pluripotency pro-
moters. A logistic regression model was fit to normalized
data features extracted in Step 1 and was followed by the
application of a shrinkage method, the least absolute
shrinkage and selection operator (LASSO) [5], which min-
imizes the sum of squared errors and puts a boundary on
the sum of the absolute value of regression coefficients.
LASSO was used to identify the best set of features among
all histone modification and TF binding data features to
predict a pluripotency gene. LASSO typically produces a
model that is both easy to interpret and has a conceivably
lower prediction error than the full model. The LASSO
regression model is also called the L1 regularization model
[5]. This means that, unlike the traditional regression
models, this model imposes an L1 norm constraint on the
regression coefficients. With this constraint, the LASSO
model forces the sum of the absolute value of the regres-
sion coefficients to be less than a fixed value and shrinks
the magnitude of certain coefficients to be set to zero;
therefore, chooses a simpler model that does not include
those coefficients. By including only important variables
in the model, LASSO reduces the number of variables in-
cluded in the model. Prior to the introduction of LASSO,
stepwise selection was widely used to choose important
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tain conditions such as when only a few variables have
strong relationships with the outcome.
The LASSO-step in our framework revealed a pluripo-
tency signature from our input TF binding and histone
modification datasets. We applied our feature selection
method on all: i) epigenetic data features; ii) TF binding
data features; and iii) on a combined set of epigenetic
and TF binding data features. This enabled us to learn a
TF binding signature, an epigenetic signature, and a
combined epigenetic and protein binding signature of
pluripotency in human and mouse ESCs. We assessed
the performance of each LASSO procedure by calculat-
ing the true-positive and false-positive rates. To do so,
we computed the true-positive and false-positive rates
and generated a receiver-operating curve (ROC). A ROC
represents the true-positive rate against the false-positive
rate at a given threshold setting. A random classifier,
with random guesses for a binary classification task, will
lead to a diagonal ROC (a.k.a., no-discrimination line)
from the bottom-left to the top-right corners. LASSO
procedure is fit using glmnet function in ‘glmnet’ pack-
age in R statistical software with these two arguments.Fig. 2 Receiver operating curves (ROCs) and area under curve values (AUC
that our computational models can predict pluripotency genes in human (Step 3. Classification model training Our platform
aims to assess the predictive power of our computation-
ally inferred pluripotency signatures by a 10-fold cross
validation procedure that uses the selected features.
These features are selected based on the LASSO proced-
ure. For hESCs and mESCs, we built three main types of
models: one for each pluripotency signature type (i.e.,
protein-binding only, histone marks only and combined)
using the features extracted in Step 2. For each analysis,
as discussed above, we built 500 models by randomly
selecting a set of negative gene examples for each model
building, and predicted the genes with pluripotency sig-
nature using each model. At this step, we assessed the
number of times we predicted each gene correctly.
Results
Epigenetic and protein-binding profiles constitute a
discriminative signature at pluripotency genes
Our models in hESCs and mESCs had significant pre-
dictive power as quantified by the Receiver Operator
Curves (ROC) and the area under the curve (AUC),
which shows the overall classification accuracy of these
models (Fig. 2). A random classifier would be expecteds) to quantify predictive power of our models. ROCs and AUCs show
a-c) and mouse (b-d) stem-cells better than random expectations
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random guess for a binary classification. In contrast, our
LASSO models – trained by histone marks only (‘epi-
genetic’), protein-binding patterns (‘protein binding’),
and combined sets of these features (‘E+P’) – could dis-
tinguish successfully between pluripotency and non-
pluripotency genes >70 % of the time in either hESCs or
mESCs. For comparison purposes, we also assessed the
added predictive power of gene expression levels by in-
cluding them into our logistic regression models at Step
3 (Fig. 2). Our analyses showed that the best scoring
models are obtained when histone modifications and
protein-binding datasets are integrated, which empha-
sizes the added value of building integrative models
(AUC in hESCs: 0.703; AUC in mESCs: 0.735; Fig. 2c-d).
Interestingly, in both cases, incorporating mRNA expres-
sion data along with protein binding and epigenetic data-
sets did not further improve the models’ performances.
This observation points out that in the existence of com-
prehensive epigenetic and protein binding datasets, infor-
mation in gene expression datasets are redundant.
Conserved features of a pluripotency gene signature in
human and mouse ESCs
Next, we focused on data features selected using our
LASSO procedure to uncover human and mouse
pluripotency signatures. The features selected by our
LASSO procedure are shown in Fig. 3. Note that gene
expression values were not among selected features.
Thus, we performed the remainder of our analyses using
protein-binding characteristics, histone modifications, andFig. 3 Genomic signatures obtained via LASSO feature selection. Signature
Data features enriched at pluripotency gene promoters are depicted w
promoters are depicted with blue down-facing trianglescombined models (epigenetic + protein binding). Though
the exact features did not always overlap, our analyses in-
dicate that the signature of pluripotency genes in hESCs
and mESCs share a conserved enrichment for the binding
of specific protein complexes or histone modification
regulation.
First, consistent with its role as a master transcriptional
regulator of pluripotency [20], we identified OCT4 bind-
ing patterns to be important predictors of pluripotency
genes. Notably, both breadth and count of this TF were
predictive of pluripotency, implying binding of multiple
OCT4 proteins over a continuous locus around pluripo-
tency gene promoters.
Extreme H3K4me3 breadth is associated with cell
identity genes, which include pluripotency genes in
mouse and human ESCs [2, 21]. Consistent with this
finding, we found that H3K4me3 breadth is a significant
predictor of pluripotency genes both in mESCs (top pre-
dictor in the histone modification model) and hESC (top
3rd predictor in the histone modification model). Inter-
estingly, the distance to the closest H3K4me3 domain
was a negative predictor of pluripotency in hESCs, im-
plying the importance of having an H3K4me3 domain
closer to the TSS. Further supporting the link between
H3K4me3 breadth and cell identity, the breadth of de-
position of several proteins that are known to associate
with H3K4me3 marked nucleosomes, was also predictive
for pluripotency both in mESCs and hESCs. These in-
clude the JARID1B/Kdm5b H3K4me3 demethylase [22],
H3K4me3 trimethyltransferase complex subunits Ash2l,
WDR5 and Mll2 [23], and the nucleosome remodelers discovered at pluripotency genes in human (a) and mouse (b) ESCs.
ith red up-facing triangles; features depleted at pluripotency gene
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of their link to H3K4me3, many of these predictive pro-
teins have been shown to modulate ESC pluripotency.
Indeed, Chd1 has also been shown to act as an import-
ant regulator of pluripotency in mESCs [25]. The pres-
ence of Jarid1b/Kdm5b is essential for the ability of
mESCs to differentiate properly along the neural
lineage [26]. Finally, several members of the H3K4me3
deposition complex have also been directly involved in
the maintenance or acquisition of stem cell pluripo-
tency [27–32], which is consistent with their predictive
value for pluripotency genes. These published findings
support the validity of our approach for identifying a
bona fide signature of pluripotency genes in mamma-
lian ESCs.
Other features common to mouse and human pluripo-
tency gene–associated signatures include transcriptional
elongation or transcriptional activity characteristics,
including the H3K36me3 histone mark [33], elongation
factor Spt5, binding of RNA Polymerase II (Pol2) or tran-
scription initiation protein TFIIIC. This is in line with
findings showing that the H3K36 methyl-transferase Setd2
is required for the differentiation of mESCs along the
endoderm lineage [34]. Interestingly, breadth or fold-
enrichment of H3K79 methylation, which is another mark
of transcriptional elongation, is also predictive according
to our models (Fig. 3b). This finding is in agreement with
recent findings that identified Dot1l, the enzyme that reg-
ulates the deposition of this mark, as an important regula-
tor of mESC pluripotency and reprogramming [35, 36].
Our computational models identified a genomic sig-
nature, which suggests that ESCs require a very spe-
cific and precise transcriptional regulation mode for
maintenance of pluripotency.
In the context of chromatin state, the pluripotency
gene signatures we identified were generally enriched for
active chromatin states. Our results also revealed that
the epigenetic component of the pluripotency signature
is generally composed of increased activating relative to
repressive epigenetic marks. For example in hESCs, we
identified importance of several acetylation marks in-
cluding acetylation of H2BK5 and H3K18 residues. Simi-
larly, in mESCs, we found that activating marks,
including H3K79me2, H3K4me3 and H3K36me3 feature
prominently in the epigenetic pluripotency signature. As
part of the hESC pluripotency signature, we identified a
depletion of H3K9me3 peaks at putative pluripotency
promoters, though not captured in mESCs. H3K9me3 is
a repressive mark that is thought to target constitutive
heterochromatin [37]. Together with the enrichment for
active chromatin marks, the reduced number of
H3K9me3 in the vicinity of pluripotency genes is con-
sistent with the fact that, as expected, these promoters
have active chromatin characteristics in ESCs.In contrast, our models found increased binding of
EZH2 (Enhancer of Zeste homolog 2) at pluripotency
gene promoters in mESCs. EZH2 is the catalytic subunit
of the PRC2 complex, which is responsible for depos-
ition of the H3K27me3 chromatin mark, a mark trad-
itionally associated with facultative heterochromatin
[37]. Though the presence of this repressive complex at
pluripotency genes may seem paradoxical, genome-wide
analyses have revealed that the PRC2 complex co-
localizes with many repressed targets of pluripotency
master regulators, OCT4, SOX2, and NANOG, in hESCs
[38]. Thus, our models may have captured a subset of
developmental genes that must be repressed in ESC to
maintain pluripotency, but are poised for subsequent
(and requisite) activation during differentiation [39], and
may thus represent a key subset of important ‘bivalent’
genes, i.e., genes marked with both activating and re-
pressive epigenetic marks [21].
To understand whether there is a distribution bias for
the predictive features, we generated violin plots that
represent the distribution of signed distance from the
TSS (Additional file 2: Figure S1). These analyses re-
vealed that there are no notable biases in the genomic
distribution of these features: the distance is centered
around TSS and the location of both TF binding and
histone modification marks are evenly distributed in the
upstream and downstream of genes. We also observed
that most features are close to the TSS (within 10 kb),
whereas some can be as far as 100 Kbps. Interestingly,
we didn’t observe a significant difference in terms of the
location of TF and histone modification features.
Different data features contribute to the pluripotency
signature
Our feature extraction and selection steps enabled us to
study different characteristics of ChIP-seq datasets and
assess the importance of each of these characteristics in
marking pluripotency gene promoters in stem cells. We
found that one of the most robust features of pluripo-
tency associated signatures in our protein binding and
histone modification datasets is the number of peaks an-
notated with pluripotency genes, as well as the spread of
the binding over the locus (Fig. 3). For proteins, this im-
plies that the same protein binds at multiple loci around
the pluripotency gene promoter. For histone marks, this
implies that there are multiple disjoint genomic loci
marked with that particular histone mark in the vicinity
of the TSS of a pluripotency gene. Most genomic studies
reduce the TF binding and epigenetic mark datasets into
binary information (i.e., whether there is a TF binding or
not). Our results imply that future studies will benefit
from taking into consideration not only the existence of
a mark or a protein binding event, but also the spread of
TF binding or histone modification at a locus.
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datasets are correlated
To understand the relationships between the different fea-
tures of ChIP-seq peaks, we calculated the Spearman rank
correlation coefficient values between these features using
all human and mouse genes with signal in at least one of
these datasets. Our analysis showed that the breadth of an
epigenetic mark is highly correlated with the number of
times that promoter is tagged with that specific histone
mark (Additional file 3: Figure S2), which could indicate
that i) the experiments were likely not sequenced to satur-
ation or ii). Current peak callers may fail to precisely de-
fine boundaries of expanded ChIP-seq peaks and call
multiple disjoint peaks in lieu of expanded histone mark
deposition. Consistently, we identified the same relation-
ship between the breadth of protein binding peaks and the
number of times that a protein is bound to the promoter.
To better understand how breadth and count features of
histone modification marks are related and how this could
impact our models, we calculated the correlation coeffi-
cient for the selected datasets (Additional file 4: Table S2).
This analysis revealed that count and breadth of histone
modification marks are typically positively yet moderately
correlated (correlation coefficient ~0.22 for both human
and mouse. Moreover, this analysis also revealed that the
selected features in our models are typically not highly
correlated, consistent with the ability of LASSO to enable
the selection of features linked to pluripotency, yet uncor-
related to each other.
Candidate pluripotency genes can be predicted
computationally
Using our predictive models, we next searched for genes
with no known role in pluripotency that exhibit ourFig. 4 Analyses of predicted embryonic stem cell regulators. a Computatio
human and mouse expression datasets. b Motifs enriched in the promoter
active in ESCs such as LEF1 and SP1, shades of red represent -log p-valuescomputational signature. In this way, we were able to pre-
dict 593 putative pluripotency genes in human and 3211
in mouse ESCs by identifying genes that are robustly pre-
dicted as pluripotent in ≥90 % of our resampled models
(listed in Additional file 5: Table S3). We identified that
181 of these genes are common between mice and human
(Additional file 5: Table S3), which is greater than
expected by chance (Fisher overlap p-value <2.2e-16). This
suggests that the pluripotency network is likely to be
conserved between mouse and human ESC. To evaluate
whether these predicted genes have elevated gene expres-
sion levels in embryonic stem-cell datasets, we first evalu-
ated their mRNA expression levels in ESCs, using
publically available RNA-seq datasets. Our analyses
showed that these genes are expressed at significantly
higher levels in both human and mouse ESCs compared
to all other expressed genes (Fig. 4a). However, it is un-
likely that our models merely capture the most highly
expressed genes in ESCs, because gene expression datasets
alone are not as predictive as integrated models obtained
from multiple histone mark and protein binding datasets
in hESCs (Additional file 6: Figure S3).
Next, we used the EnrichR tool (http://amp.pharm.mss-
m.edu/Enrichr/) to explore the TF regulatory patterns
among the promoters for these genes. We found
these genes are indeed enriched in binding of pluripo-
tency related proteins in diverse datasets obtained
from public ChIP-seq and ChIP-chip experiments,
such as SP1, NANOG and MYC (Fig. 4b), which was con-
sistent with Gene Set Enrichment Analyses (Additional
file 7: Figure S4). These observations suggest that our
framework can identify genes with potentially import-
ant roles in pluripotency functions in ESCs. The list
of genes predicted by our models is available as anally predicted pluripotency genes exhibit elevated expression in
s of predicted pluripotency genes in human and mouse including TFs
of enrichment
Kurum et al. Biology Direct  (2016) 11:47 Page 9 of 14resource for the stem cell research community in
Additional file 5: Table S3.
Discussion
We built a three-step computational framework to un-
cover consistent predictors of pluripotency genes in hu-
man and mouse ESCs and assess their predictive power.
These predictors consist of: i) an enrichment for pluripo-
tency regulators, ii) a signature of increased H3K4me3
spread and iii) increased marks of regulation of transcrip-
tional elongation and initiation. Together, these findings
are consistent with the existence of a complex and inte-
grative epigenomic signature that, using our model, can
be exploited to flag important pluripotency genes.
We were able to identify common patterns predictive
of pluripotency genes in mouse and human ESCs, sug-
gesting conserved pathways may regulate the chromatin
landscape of pluripotency genes across species. However,
specific features were found to be predictive in only
mouse (e.g. Sin3a distance) or human (e.g. H3K9me3
count). The existence of non-overlaping features predict-
ive of pluripotency between mouse and human could re-
sult from the fact that some features were only available
in one of the species, and that there are some partial
cryptic redundancy over these features. However, it may
also likely be the result of fundamental differences in the
biology of hESC and mESC [40, 41], with in particular
hESC being in a less ‘naïve’ state than their murine
counterparts. Thus, the differences we observed in the
chromatin signature of pluripotency genes may also be a
symptom of species differences of or of these divergent
states of ‘naïve-ness’, and could help shed light on the
mechanisms underlying these differences.
Although we were able to identify features predictive
in marking known pluripotency genes, the predictive
power of our models remains limited (AUC~0.7), sug-
gesting the existence of other factors for the importance
of a gene’s role in pluripotency in addition to the gen-
omic signature at its promoters, for example existence
of distal regulatory elements or binding of a long non-
coding RNA. In the future, the predictive power of such
models might be expanded with the inclusion of novel
datasets. Taken together, we believe our findings will en-
able the community to further integrate novel and import-
ant data characteristics into their studies and, in turn,
foster a deeper understanding of specific epigenomic data-
sets and, perhaps, the hypothesized ‘histone code’ [1].
We believe our study can particularly be informative
in advancing our understanding of induced pluripotent
cells and cancer stem cells. The ‘stem-like’ characteristics
of Cancer Stem Cells (CSCs), i.e., self-renewal and prolif-
eration, make cancer treatment even more difficult [42].
Indeed, these cells can remain quiescent for long periods
of time and then get reactivated leading to cancerrelapse. Therefore, it will be essential to understand the
epigenomic characteristics of other types of stem cells
such as CSCs and to compare these characteristics to
the ones we identified in embryonic stem cells (ESCs).
We foresee that our work can be useful in the future in
characterizing CSCs in two main directions. First, this
genomic signature that we captured (i.e., 181 genes that
are predicted to be important for pluripotency in both in
human and mouse cells) could be used to assess the
pluripotency characteristics of cancer cells. Moreover,
with the increase of genomics information in CSCs,
similar statistical models of cancer pluripotency can
eventually be built and compared to the embryonic
stem/pluripotency signature. These efforts might help in
identifying CSCs in cancer cells and ultimately be es-
sential in developing therapeutic strategies against
chemo-resistant cancers. In addition, our models can
be significant in improving our understanding of in-
duced pluripotent stem cells (iPSCs) and in which ways
they are similar and different than ESCs. In recent
years, a growing compendium of genomic and epige-
nomic profiling data has started to be generated in hu-
man and mouse iPSCs [43]. Together with conserved
pluripotency candidates inferred from our models (i.e.,
181 genes) as biomarkers, these datasets could be
mined to evaluate the degree of achieved pluripotency
during the reprogramming process. Moreover, our
models could be extended to study the genomic and
epigenomic landscape associated with cell-type-specific
genes in differentiated cell types. Moreover, recent evi-
dence shows that in addition to cell-type-specific pro-
moters, cell-type-specific enhancers also have distinct
epigenomic profiles [19, 44]. Although it is challenging
to identify a true set of cell-specific enhancers due to
distal promoter-enhancer targeting, with the increasing
amount of three-dimensional chromatin-interaction
datasets, such as ChIA-PET datasets, this approach
could be extrapolated to study the signature at cell-
type-specific enhancers in a systematic manner.
Reviewers’ comments
Reviewer’s report 1: Zoltan Gaspari
Reviewer summary:
The presented research deals with the identification of
pluripotency genes from TF binding, epigenetic signature
and gene expression data using a machine-learning ap-
proach. I think that the study is both timely and well-
conducted and the results are novel and important and the
list of putative pluripotency genes merits further investiga-
tions. The relatively modest performance of the predictions
reveal the importance of further research in the area.
Authors’ response: We thank the reviewer for his sup-
portive comments of our study and for highlighting the
general interest of our biological findings. We have made
Kurum et al. Biology Direct  (2016) 11:47 Page 10 of 14a concerted effort to address all of his concerns. We list
each criticism and briefly describe how we have ad-
dressed it in our revised manuscript. Changes made in
the revised manuscript are marked in yellow.
Reviewer recommendations to authors:
Major recommendations:
It might be worth providing a list of the identified
pluripotency genes and their relationship in mouse and
human (as supplementary material).
Authors’ response: We have previously provided a list
of genes in human and mouse along with their correct
prediction scores (Additional file 5: Table S3). To un-
cover the relation between human and mouse predic-
tions, we further studied the genes that are frequently
predicted as pluripotent in our models (≥90 %). Our
analyses revealed that there is statistically significant
overlap between these predictions, where 181 of these
genes are shared between human and mouse (enrich-
ment p-value using fisher’s exact test based on 30 K total
genes is <2.2e-16). We have included this information
into our manuscript (page 17) and also provided this list
in the updated Additional file 5: Table S3.
Is Z-score-based normalization justified in all cases? I
mean, there might be bimodal or more complex distance
distributions. Please comment on that whether there are
such cases and whether these can affect the conclusions.
Authors’ response: The purpose of the standardization
was to follow the common practice in LASSO-type regu-
larizations. Before employing LASSO regularization, it is
recommended to standardize variables so that the solu-
tion does not depend on the measurement unit. In
addition, the logistic regression model we used in our
manuscript does not place any normality assumptions
on the covariates. We clarified this choice in the revised
manuscript (page 10).
Minor recommendations:
According to the description, only the distance from
the TSS is considered. Please comment on whether the
direction could be important (and whether it would be
technically feasible to consider it).
Authors’ response: We thank the reviewer for this com-
ment and for giving us an opportunity to clarify the way
we processed this data in our models. In our models, we
used the signed distance from the TSS, where negative
values mean upstream of the TSS and positive values
mean downstream of the TSS. We have clarified this in
the manuscript (page 9).
It might be worth to provide some notes about the
precision of the location of the epigenetic marks/TF
binding sites with highest found predictive values.
Authors’ response: We thank the reviewer for this in-
teresting suggestion. To answer this question, we gener-
ated violin plots that represent the distribution of signed
distance from the TSS for selected predictive features.We have included this as Additional file 2: Figure S1 and
discussed these results (page 15) in our revised manu-
script. Our analyses revealed that there aren’t any not-
able biases in the genomic distribution of these features:
the distance is centered around TSS and the location of
both TF binding and histone modification marks are
evenly distributed in the upstream and downstream of
genes. We also observed that most features are close to
the TSS within 10 kb, whereas some can be as far as
100 Kbps. Interestingly, we didn’t observe a significant
difference in terms of the location of TF and histone
modification features.
It could be worth to add a short discussion about the
differences between hESCs and mESCs, to what extent
might these come from our differential knowledge/data
availability and existing biological differences between
the organisms.
Authors’ response: We thank the reviewer for this
suggestion, which will greatly enhance the biological
interpretation of our findings. We have now included
a paragraph in the discussion to address the potential
causes of the differences in predictive features be-
tween mESCs and hESCs, which we also copy below:
“We were able to identify common patterns predictive
of pluripotency genes in mouse and human ESCs, sug-
gesting conserved pathways may regulate the chromatin
landscape of pluripotency genes across species. However,
specific features were found to be predictive in only
mouse (e.g. Sin3a distance) or human (e.g. H3K9me3
count). The existence of non-overlaping features predict-
ive of pluripotency between mouse and human could re-
sult from the fact that some features were only available
in one of the species, and that there are some partial
cryptic redundancy over these features. However, it may
also likely be the result of fundamental differences in the
biology of hESC and mESC [1, 2], with in particular
hESC being in a less ‘naïve’ state than their murine
counterparts. Thus, the differences we observed in the
chromatin signature of pluripotency genes may also be a
symptom of species differences of or of these divergent
states of ‘naïve-ness’, and could help shed light on the
mechanisms underlying these differences.”
Please provide more details about the relationship be-
tween the count and breadth of certain marks. In these
cases it could be important to see the exact distribution
of the data correlated.
Authors’ response: We thank the reviewer for pointing
this out. To better understand how breadth and count
features of histone modification marks are related and
how this could impact our models, we calculated the
correlation coefficient for the selected datasets and pro-
vided these in Additional file 4: Table S2. This analysis
revealed that count and breadth of histone modification
marks are typically positively yet moderately correlated
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mouse. Moreover, this analyses also revealed that the se-
lected features in our models are typically not highly
correlated, consistent with the ability of LASSO to en-
able the selection of features linked to pluripotency, yet
uncorrelated to each other (page 16).
Please clarify that in Step3 (Classification and model
training) you have selected the negative gene set _in
addition_ to the list of known pluripotency genes and that
this 500 times repeated procedure is the same as men-
tioned in “Identification of ‘canonical’ pluripotency genes”
Authors’ response: Based on the reviewer’s suggestion,
we clarified the relation between Step 3 and the “Identi-
fication of ‘canonical’ pluripotency genes” sections to the
end of page 7. “This process, in which we used the
known pluripotency genes and selected negative controls
randomly, was repeated 500 times and, at each run, non-
pluripotency genes were selected in equal numbers rela-
tive to their pluripotency gene counterparts.”
We also clarified the relation between these parts by
referring to the “Identification of ‘canonical’ pluripo-
tency genes” section at the end of Step 3 section on page
11. “For each analysis, as we discussed in the identifica-
tion of canonical genes section, we built 500 models by
randomly selecting a set of negative gene examples for
each model building, and predicted the genes with pluri-
potency signature using each model.”
In Additional file 4: Table S2, please indicate which
genes you regard as putative pluripotency genes.
Authors’ response: We chose 90 % to be the cutoff
value, that is, a gene with a prediction rate that is greater
than 90 % is regarded as putative pluripotency gene. In the
revised Additional file 5: Table S3, we highlighted these
genes and included this cutoff criterion at the top of the
file. We also included genes that are common between hu-
man and mouse into the Additional file 5: Table S3.
I would suggest combining all data into a single multi-
tab Excel file for easier handling.
Authors’ response: Predictions from human and mouse
are provided in the tabs of Additional file 5: Table S3.
We keep human and mouse predictions in separate tabs,
yet provide the common genes between human and
mouse in this.
Reviewer’s report 2: Piotr Zielenkiewicz
Reviewer summary:
I have found the paper very interesting. Authors ap-
plied a Lasso method for modelling epigenetic regulation
of genes in human and mouse embryonic stem cells
(ESCs). It was a good read.
I am, however, confused as the authors did not show
what is novel in their approach. The Lasso regression
model has already been applied for the construction of
microRNA-target regulatory network (see the paper “ALasso regression model for the construction of
microRNA-target regulatory networks”, Bioinformatics.
2011 Sep 1;27(17):2406–13) and for modelling of impact
of histone modifications on gene activity (see “Modelling
epigenetic regulation of gene expression in 12 human
cell types reveals combinatorial patterns of cell-type-
specific genes”, IET Syst Biol. 2014 Jun;8(3):104–15).
The authors seem to be unaware of these contributions.
This leads to a confusion about the relation of the Lasso
algorithm they used to the previous applications. On the
positive side, it should be mentioned that the Authors’
approach properly predicts gene activity.
This is very strong part of the paper.
Authors’ response: We thank the referee for his
thoughtful and constructive comments and his appreci-
ation of our work. We have made a concerted effort to
address all of his concerns. We list each criticism and
briefly describe how we have addressed it.
I believe the Authors should in more detail discuss the
biological significance of their study i.e. describe what is the
impact of expanded trimethylation of histone H3 at lysine 4
on activity of apoptotic genes and cellular metabolism.
The paper “The Warburg effect version 2.0: Metabolic
reprogramming of cancer stem cells, Menendez et al.
2013, Cell Cycle. 2013 Apr 15;12(8):1166–79” can be
particularly useful in this respect.
Authors’ response: We thank the reviewer for this great
suggestion. We have included a detailed discussion on
how this study can be expanded and utilized to under-
stand epigenomics characteristics of induced pluripotent
stem cells and cancer stem cells in the discussion section
of our manuscript. We also copied this below:
“We believe our study can particularly be informative
in advancing our understanding of induced pluripotent
cells and cancer stem cells. The ‘stem-like’ characteristics
of Cancer Stem Cells (CSCs), i.e., self-renewal and prolif-
eration, make cancer treatment even more difficult [3].
Indeed, these cells can remain quiescent for long periods
of time and then get reactivated leading to cancer re-
lapse. Therefore, it will be essential to understand the
epigenomic characteristics of other types of stem cells
such as CSCs and to compare these characteristics to
the ones we identified in embryonic stem cells (ESCs).
We foresee that our work can be useful in the future in
characterizing CSCs in two main directions. First, this
genomic signature that we captured (i.e., 181 genes that
are predicted to be important for pluripotency in both in
human and mouse cells) could be used to assess the
pluripotency characteristics of cancer cells. Moreover,
with the increase of genomics information in CSCs,
similar statistical models of cancer pluripotency can
eventually be built and compared to the embryonic
stem/pluripotency signature. These efforts might help in
identifying CSCs in cancer cells and ultimately be
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chemo-resistant cancers.
In addition, our models can be significant in improv-
ing our understanding of induced pluripotent stem cells
(iPSCs) and in which ways they are similar and different
than ESCs. In recent years, a growing compendium of
genomic and epigenomic profiling data has started to be
generated in human and mouse iPSCs [4]. Together with
conserved pluripotency candidates inferred from our
models (i.e., 181 genes) as biomarkers, these datasets
could be mined to evaluate the degree of achieved pluri-
potency during the reprogramming process.”
Reviewer recommendations to authors:
References to previous similar contributions should be
added. The discussion section should be extended to
contain the biological significance of the results.
Authors’ response: We thank the reviewer for alerting
us to these interesting studies and for pointing out the
strengths of our study; we have included references to
similar studies and included a brief discussion to high-
light the novelty of our work in the introduction.
We agree with the reviewer that LASSO regression
model has been used in literature several times. We have
included a summary of the literature on LASSO-type
regularizations to the introduction of our paper and
highlighted in which ways our study is similar and differ-
ent than some of these previous studies. Similar to previ-
ous studies published in the literature, we also employed
the traditional LASSO regression model, yet we differ by
utilizing LASSO-type regularization to address a new set
of questions. We included the following paragraph to the
introduction of the revised manuscript to summarize
some of the literature on LASSO-type models and to clar-
ify the contribution of our paper:
“LASSO is a regression method that enables effective
feature selection and model interpretation. LASSO-type
regularizations have been applied to a wide range of ap-
plications in genetics and epigenetics [5–8]. In recent
years, it has been successfully applied on learning diverse
genomic and epigenomic patterns, including predicting
targets of microRNAs from gene expression data [7],
gene expression levels from histone modification marks
[6], and from copy number variations [5]. In this manu-
script, we employed LASSO models to address the fol-
lowing questions in human and mouse ESCs: is there a
specific (epi-)genomic signature that marks pluripotency
gene promoters in human and mouse stem cells? Can
this signature be used to predict novel pluripotency
genes? Are features of this pluripotency signature con-
served between human and mouse embryonic stem
cells? Indeed, we found a genomic signature, predictive
of pluripotency in human and mouse embryonic stem
cells, which is partially conserved across both organisms.
Our main contribution is, in addition to utilizingLASSO-type regularization to effectively address the
above-mentioned questions; with our computational
models we quantified the predictive power of this signa-
ture for identifying important genes for ‘stem cell state’.”
Minor issues:
The Lasso method (the knowledge of which is rare)
should be described to at least the same level of detail as
ROC curves (known to everybody).
Authors’ response: We thank the reviewer for his useful
feedback; we have included the following detailed de-
scription of LASSO models to the end of page 10 in our
manuscript.
“The LASSO regression model is also called the L1
regularization model, that is, unlike the traditional
regression models; this model imposes an L1 norm con-
straint on the regression coefficients. With this con-
straint, the LASSO model forces the sum of the absolute
value of the regression coefficients to be less than a fixed
value and shrinks the magnitude of certain coefficients
to be set to zero; therefore, chooses a simpler model that
does not include those coefficients. By including only
important variables in the model, LASSO reduces the
number of variables included in the model. Prior to the
introduction of LASSO, stepwise selection was widely used
to choose important variables; however, this method can
only work under certain conditions such as when only a
few variables have strong relationships with the outcome.”Additional files
Additional file 1: Table S1. Accession codes for epigenetic and protein-
binding datasets used in our computational framework. (XLSX 62 kb)
Additional file 2: Figure S1. Distribution of distance to TSS for selected
features (A) human and (B) mouse. (PDF 376 kb)
Additional file 3: Figure S2. Epigenetic and protein binding dataset
correlations. Correlations between a subset of epigenetic and protein
binding data features (assessed by Spearman correlation coefficient)
indicate that certain datasets and features are highly correlated with each
other in human (A-B-C) and mouse (D-E-F) embryonic stem cells. (PDF
11059 kb)
Additional file 4: Table S2. Pairwise correlation coefficients between
selected histone modification marks including count and breadth data
features. (XLSX 42 kb)
Additional file 5: Table S3. Predicted stemness regulators in human
and mouse ESCs from the logistic regression models with LASSO (E+P).
(XLSX 834 kb)
Additional file 6: Figure S3. Receiver operating curves (ROCs) and area
under curve values (AUCs) to quantify predictive power of our models
including models built with gene expression data alone in human (A-C)
and mouse (B-D). (PDF 1675 kb)
Additional file 7: Figure S4. Gene Set Enrichment Analyses of genes
ranked with respect to the number of times each gene is predicted as
‘pluripotent’ in LASSO models. (PDF 153 kb)Abbreviations
AUC: Area under the curve; ESC: Embryonic stem cell; LASSO: Least absolute
shrinkage and selection operator; ROC: Receiver operating curve;
TF: Transcription factor; TSS: Transcriptional start site
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